nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CYP3A4—Temozolomide—melanoma	0.166	0.385	CbGbCtD
Darifenacin—CYP2D6—Vemurafenib—melanoma	0.143	0.332	CbGbCtD
Darifenacin—CYP3A4—Vemurafenib—melanoma	0.0908	0.211	CbGbCtD
Darifenacin—CYP3A4—Docetaxel—melanoma	0.0311	0.0724	CbGbCtD
Darifenacin—Ulcerative stomatitis—Dactinomycin—melanoma	0.00801	0.0233	CcSEcCtD
Darifenacin—Dry skin—Vemurafenib—melanoma	0.00435	0.0127	CcSEcCtD
Darifenacin—Accidental injury—Carmustine—melanoma	0.00391	0.0114	CcSEcCtD
Darifenacin—Thinking abnormal—Carmustine—melanoma	0.00378	0.011	CcSEcCtD
Darifenacin—Infestation NOS—Vemurafenib—melanoma	0.00366	0.0107	CcSEcCtD
Darifenacin—Infestation—Vemurafenib—melanoma	0.00366	0.0107	CcSEcCtD
Darifenacin—Bladder pain—Bleomycin—melanoma	0.00358	0.0104	CcSEcCtD
Darifenacin—Vaginal inflammation—Temozolomide—melanoma	0.00334	0.00974	CcSEcCtD
Darifenacin—Mouth ulceration—Dactinomycin—melanoma	0.00334	0.00973	CcSEcCtD
Darifenacin—Oedema peripheral—Vemurafenib—melanoma	0.00324	0.00942	CcSEcCtD
Darifenacin—Vaginal infection—Temozolomide—melanoma	0.00316	0.00919	CcSEcCtD
Darifenacin—Injury—Bleomycin—melanoma	0.00313	0.00911	CcSEcCtD
Darifenacin—Erythema multiforme—Vemurafenib—melanoma	0.00311	0.00904	CcSEcCtD
Darifenacin—Dry eye—Temozolomide—melanoma	0.00309	0.00899	CcSEcCtD
Darifenacin—Eye disorder—Vemurafenib—melanoma	0.00307	0.00894	CcSEcCtD
Darifenacin—Abnormal vision—Carmustine—melanoma	0.00302	0.00879	CcSEcCtD
Darifenacin—Mental disability—Carmustine—melanoma	0.003	0.00874	CcSEcCtD
Darifenacin—Angiopathy—Vemurafenib—melanoma	0.00298	0.00868	CcSEcCtD
Darifenacin—Mediastinal disorder—Vemurafenib—melanoma	0.00296	0.00862	CcSEcCtD
Darifenacin—Cerebrovascular accident—Bleomycin—melanoma	0.00294	0.00855	CcSEcCtD
Darifenacin—Abnormal vision—Temozolomide—melanoma	0.00292	0.00849	CcSEcCtD
Darifenacin—Mental disability—Temozolomide—melanoma	0.0029	0.00845	CcSEcCtD
Darifenacin—Dysgeusia—Vemurafenib—melanoma	0.0028	0.00815	CcSEcCtD
Darifenacin—Back pain—Vemurafenib—melanoma	0.00277	0.00805	CcSEcCtD
Darifenacin—Injury—Carmustine—melanoma	0.00273	0.00796	CcSEcCtD
Darifenacin—Cough—Vemurafenib—melanoma	0.0025	0.00727	CcSEcCtD
Darifenacin—Arthralgia—Vemurafenib—melanoma	0.00243	0.00709	CcSEcCtD
Darifenacin—Face oedema—Carmustine—melanoma	0.00242	0.00706	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00242	0.00704	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00242	0.00704	CcSEcCtD
Darifenacin—Face oedema—Temozolomide—melanoma	0.00234	0.00682	CcSEcCtD
Darifenacin—Anaphylactic shock—Vemurafenib—melanoma	0.00233	0.0068	CcSEcCtD
Darifenacin—Infection—Vemurafenib—melanoma	0.00232	0.00675	CcSEcCtD
Darifenacin—Nervous system disorder—Vemurafenib—melanoma	0.00229	0.00666	CcSEcCtD
Darifenacin—Skin disorder—Vemurafenib—melanoma	0.00227	0.0066	CcSEcCtD
Darifenacin—Dry skin—Temozolomide—melanoma	0.00222	0.00648	CcSEcCtD
Darifenacin—Breast disorder—Temozolomide—melanoma	0.00219	0.00639	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00219	0.00636	CcSEcCtD
Darifenacin—Stomatitis—Bleomycin—melanoma	0.00216	0.00629	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Temozolomide—melanoma	0.00214	0.00623	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00213	0.00619	CcSEcCtD
Darifenacin—Bronchitis—Temozolomide—melanoma	0.00202	0.00587	CcSEcCtD
Darifenacin—Stomatitis—Dactinomycin—melanoma	0.00202	0.00587	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Vemurafenib—melanoma	0.00201	0.00587	CcSEcCtD
Darifenacin—Constipation—Vemurafenib—melanoma	0.002	0.00581	CcSEcCtD
Darifenacin—Erectile dysfunction—Temozolomide—melanoma	0.00193	0.00562	CcSEcCtD
Darifenacin—Weight increased—Temozolomide—melanoma	0.00191	0.00556	CcSEcCtD
Darifenacin—Clotrimazole—CYP17A1—melanoma	0.00189	0.524	CrCbGaD
Darifenacin—Stomatitis—Carmustine—melanoma	0.00189	0.00549	CcSEcCtD
Darifenacin—Urinary tract infection—Carmustine—melanoma	0.00188	0.00548	CcSEcCtD
Darifenacin—Infestation—Temozolomide—melanoma	0.00187	0.00545	CcSEcCtD
Darifenacin—Infestation NOS—Temozolomide—melanoma	0.00187	0.00545	CcSEcCtD
Darifenacin—Pharyngitis—Dactinomycin—melanoma	0.00184	0.00536	CcSEcCtD
Darifenacin—Stomatitis—Temozolomide—melanoma	0.00182	0.00531	CcSEcCtD
Darifenacin—Urinary tract infection—Temozolomide—melanoma	0.00182	0.00529	CcSEcCtD
Darifenacin—Erythema multiforme—Dactinomycin—melanoma	0.00175	0.00511	CcSEcCtD
Darifenacin—Sinusitis—Temozolomide—melanoma	0.00175	0.00511	CcSEcCtD
Darifenacin—Hallucination—Carmustine—melanoma	0.00173	0.00503	CcSEcCtD
Darifenacin—Hypersensitivity—Vemurafenib—melanoma	0.00172	0.00501	CcSEcCtD
Darifenacin—Oedema peripheral—Carmustine—melanoma	0.00171	0.00498	CcSEcCtD
Darifenacin—Visual disturbance—Docetaxel—melanoma	0.0017	0.00496	CcSEcCtD
Darifenacin—Asthenia—Vemurafenib—melanoma	0.00167	0.00488	CcSEcCtD
Darifenacin—Visual impairment—Carmustine—melanoma	0.00167	0.00487	CcSEcCtD
Darifenacin—Hallucination—Temozolomide—melanoma	0.00167	0.00486	CcSEcCtD
Darifenacin—Pharyngitis—Temozolomide—melanoma	0.00167	0.00485	CcSEcCtD
Darifenacin—Urinary tract disorder—Temozolomide—melanoma	0.00166	0.00483	CcSEcCtD
Darifenacin—Oedema peripheral—Temozolomide—melanoma	0.00165	0.00482	CcSEcCtD
Darifenacin—Pruritus—Vemurafenib—melanoma	0.00165	0.00481	CcSEcCtD
Darifenacin—Urethral disorder—Temozolomide—melanoma	0.00165	0.00479	CcSEcCtD
Darifenacin—Eye disorder—Carmustine—melanoma	0.00162	0.00473	CcSEcCtD
Darifenacin—Visual impairment—Temozolomide—melanoma	0.00162	0.00471	CcSEcCtD
Darifenacin—Diarrhoea—Vemurafenib—melanoma	0.0016	0.00465	CcSEcCtD
Darifenacin—Erythema multiforme—Temozolomide—melanoma	0.00159	0.00462	CcSEcCtD
Darifenacin—Eye disorder—Temozolomide—melanoma	0.00157	0.00457	CcSEcCtD
Darifenacin—Dizziness—Vemurafenib—melanoma	0.00154	0.00449	CcSEcCtD
Darifenacin—Angiopathy—Temozolomide—melanoma	0.00152	0.00444	CcSEcCtD
Darifenacin—Mental disorder—Carmustine—melanoma	0.00152	0.00443	CcSEcCtD
Darifenacin—Mediastinal disorder—Temozolomide—melanoma	0.00151	0.00441	CcSEcCtD
Darifenacin—Cough—Bleomycin—melanoma	0.00151	0.0044	CcSEcCtD
Darifenacin—Vomiting—Vemurafenib—melanoma	0.00148	0.00432	CcSEcCtD
Darifenacin—Dry skin—Docetaxel—melanoma	0.00148	0.00431	CcSEcCtD
Darifenacin—Rash—Vemurafenib—melanoma	0.00147	0.00428	CcSEcCtD
Darifenacin—Mental disorder—Temozolomide—melanoma	0.00147	0.00428	CcSEcCtD
Darifenacin—Dermatitis—Vemurafenib—melanoma	0.00147	0.00428	CcSEcCtD
Darifenacin—Back pain—Carmustine—melanoma	0.00146	0.00426	CcSEcCtD
Darifenacin—Headache—Vemurafenib—melanoma	0.00146	0.00426	CcSEcCtD
Darifenacin—Breast disorder—Docetaxel—melanoma	0.00146	0.00425	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00145	0.00423	CcSEcCtD
Darifenacin—Dysgeusia—Temozolomide—melanoma	0.00143	0.00417	CcSEcCtD
Darifenacin—Confusional state—Bleomycin—melanoma	0.00143	0.00415	CcSEcCtD
Darifenacin—Vision blurred—Carmustine—melanoma	0.00143	0.00415	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Docetaxel—melanoma	0.00142	0.00414	CcSEcCtD
Darifenacin—Anaphylactic shock—Bleomycin—melanoma	0.00141	0.00412	CcSEcCtD
Darifenacin—Oedema—Bleomycin—melanoma	0.00141	0.00412	CcSEcCtD
Darifenacin—Back pain—Temozolomide—melanoma	0.00141	0.00412	CcSEcCtD
Darifenacin—Infection—Bleomycin—melanoma	0.0014	0.00409	CcSEcCtD
Darifenacin—Nausea—Vemurafenib—melanoma	0.00139	0.00404	CcSEcCtD
Darifenacin—Vision blurred—Temozolomide—melanoma	0.00138	0.00401	CcSEcCtD
Darifenacin—Angioedema—Temozolomide—melanoma	0.00134	0.00389	CcSEcCtD
Darifenacin—Oedema—Dactinomycin—melanoma	0.00132	0.00384	CcSEcCtD
Darifenacin—Infection—Dactinomycin—melanoma	0.00131	0.00381	CcSEcCtD
Darifenacin—Hypertension—Carmustine—melanoma	0.00131	0.0038	CcSEcCtD
Darifenacin—Palpitations—Temozolomide—melanoma	0.00129	0.00376	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Bleomycin—melanoma	0.00129	0.00375	CcSEcCtD
Darifenacin—Cough—Temozolomide—melanoma	0.00128	0.00371	CcSEcCtD
Darifenacin—Weight increased—Docetaxel—melanoma	0.00127	0.0037	CcSEcCtD
Darifenacin—Hypertension—Temozolomide—melanoma	0.00126	0.00367	CcSEcCtD
Darifenacin—Dyspnoea—Bleomycin—melanoma	0.00126	0.00367	CcSEcCtD
Darifenacin—Confusional state—Carmustine—melanoma	0.00124	0.00362	CcSEcCtD
Darifenacin—Arthralgia—Temozolomide—melanoma	0.00124	0.00362	CcSEcCtD
Darifenacin—Infestation NOS—Docetaxel—melanoma	0.00124	0.00362	CcSEcCtD
Darifenacin—Infestation—Docetaxel—melanoma	0.00124	0.00362	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00124	0.0036	CcSEcCtD
Darifenacin—Oedema—Carmustine—melanoma	0.00123	0.00359	CcSEcCtD
Darifenacin—Infection—Carmustine—melanoma	0.00123	0.00357	CcSEcCtD
Darifenacin—Dry mouth—Temozolomide—melanoma	0.00122	0.00354	CcSEcCtD
Darifenacin—Stomatitis—Docetaxel—melanoma	0.00121	0.00353	CcSEcCtD
Darifenacin—Pain—Bleomycin—melanoma	0.00121	0.00352	CcSEcCtD
Darifenacin—Tachycardia—Carmustine—melanoma	0.0012	0.00351	CcSEcCtD
Darifenacin—Confusional state—Temozolomide—melanoma	0.0012	0.0035	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.0012	0.0035	CcSEcCtD
Darifenacin—Anaphylactic shock—Temozolomide—melanoma	0.00119	0.00347	CcSEcCtD
Darifenacin—Oedema—Temozolomide—melanoma	0.00119	0.00347	CcSEcCtD
Darifenacin—Infection—Temozolomide—melanoma	0.00118	0.00345	CcSEcCtD
Darifenacin—Nervous system disorder—Temozolomide—melanoma	0.00117	0.00341	CcSEcCtD
Darifenacin—Feeling abnormal—Bleomycin—melanoma	0.00117	0.00339	CcSEcCtD
Darifenacin—Skin disorder—Temozolomide—melanoma	0.00116	0.00337	CcSEcCtD
Darifenacin—Hyperhidrosis—Temozolomide—melanoma	0.00115	0.00336	CcSEcCtD
Darifenacin—Pain—Dactinomycin—melanoma	0.00113	0.00328	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Carmustine—melanoma	0.00112	0.00327	CcSEcCtD
Darifenacin—Rhinitis—Docetaxel—melanoma	0.00112	0.00326	CcSEcCtD
Darifenacin—Insomnia—Carmustine—melanoma	0.00112	0.00325	CcSEcCtD
Darifenacin—Pharyngitis—Docetaxel—melanoma	0.00111	0.00323	CcSEcCtD
Darifenacin—Urinary tract disorder—Docetaxel—melanoma	0.0011	0.00321	CcSEcCtD
Darifenacin—Dyspnoea—Carmustine—melanoma	0.0011	0.0032	CcSEcCtD
Darifenacin—Oedema peripheral—Docetaxel—melanoma	0.0011	0.0032	CcSEcCtD
Darifenacin—Somnolence—Carmustine—melanoma	0.0011	0.00319	CcSEcCtD
Darifenacin—Urethral disorder—Docetaxel—melanoma	0.00109	0.00319	CcSEcCtD
Darifenacin—Feeling abnormal—Dactinomycin—melanoma	0.00109	0.00316	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Temozolomide—melanoma	0.00109	0.00316	CcSEcCtD
Darifenacin—Insomnia—Temozolomide—melanoma	0.00108	0.00314	CcSEcCtD
Darifenacin—Gastrointestinal pain—Dactinomycin—melanoma	0.00108	0.00314	CcSEcCtD
Darifenacin—Visual impairment—Docetaxel—melanoma	0.00108	0.00313	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Carmustine—melanoma	0.00107	0.0031	CcSEcCtD
Darifenacin—Dyspnoea—Temozolomide—melanoma	0.00106	0.0031	CcSEcCtD
Darifenacin—Somnolence—Temozolomide—melanoma	0.00106	0.00309	CcSEcCtD
Darifenacin—Erythema multiforme—Docetaxel—melanoma	0.00106	0.00307	CcSEcCtD
Darifenacin—Pain—Carmustine—melanoma	0.00106	0.00307	CcSEcCtD
Darifenacin—Constipation—Carmustine—melanoma	0.00106	0.00307	CcSEcCtD
Darifenacin—Dyspepsia—Temozolomide—melanoma	0.00105	0.00306	CcSEcCtD
Darifenacin—Eye disorder—Docetaxel—melanoma	0.00104	0.00304	CcSEcCtD
Darifenacin—Abdominal pain—Dactinomycin—melanoma	0.00104	0.00304	CcSEcCtD
Darifenacin—Hypersensitivity—Bleomycin—melanoma	0.00104	0.00303	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Temozolomide—melanoma	0.00103	0.003	CcSEcCtD
Darifenacin—Pain—Temozolomide—melanoma	0.00102	0.00297	CcSEcCtD
Darifenacin—Constipation—Temozolomide—melanoma	0.00102	0.00297	CcSEcCtD
Darifenacin—Feeling abnormal—Carmustine—melanoma	0.00102	0.00296	CcSEcCtD
Darifenacin—Asthenia—Bleomycin—melanoma	0.00101	0.00295	CcSEcCtD
Darifenacin—Angiopathy—Docetaxel—melanoma	0.00101	0.00295	CcSEcCtD
Darifenacin—Gastrointestinal pain—Carmustine—melanoma	0.00101	0.00294	CcSEcCtD
Darifenacin—Mediastinal disorder—Docetaxel—melanoma	0.00101	0.00293	CcSEcCtD
Darifenacin—Pruritus—Bleomycin—melanoma	0.001	0.00291	CcSEcCtD
Darifenacin—Feeling abnormal—Temozolomide—melanoma	0.000983	0.00286	CcSEcCtD
Darifenacin—Mental disorder—Docetaxel—melanoma	0.000978	0.00285	CcSEcCtD
Darifenacin—Abdominal pain—Carmustine—melanoma	0.000976	0.00284	CcSEcCtD
Darifenacin—Gastrointestinal pain—Temozolomide—melanoma	0.000975	0.00284	CcSEcCtD
Darifenacin—Hypersensitivity—Dactinomycin—melanoma	0.000972	0.00283	CcSEcCtD
Darifenacin—Dysgeusia—Docetaxel—melanoma	0.000952	0.00277	CcSEcCtD
Darifenacin—Asthenia—Dactinomycin—melanoma	0.000946	0.00276	CcSEcCtD
Darifenacin—Abdominal pain—Temozolomide—melanoma	0.000943	0.00275	CcSEcCtD
Darifenacin—Back pain—Docetaxel—melanoma	0.00094	0.00274	CcSEcCtD
Darifenacin—Hypersensitivity—Carmustine—melanoma	0.000909	0.00265	CcSEcCtD
Darifenacin—Diarrhoea—Dactinomycin—melanoma	0.000902	0.00263	CcSEcCtD
Darifenacin—Vomiting—Bleomycin—melanoma	0.000899	0.00262	CcSEcCtD
Darifenacin—Rash—Bleomycin—melanoma	0.000891	0.0026	CcSEcCtD
Darifenacin—Dermatitis—Bleomycin—melanoma	0.000891	0.00259	CcSEcCtD
Darifenacin—Asthenia—Carmustine—melanoma	0.000885	0.00258	CcSEcCtD
Darifenacin—Hypersensitivity—Temozolomide—melanoma	0.000879	0.00256	CcSEcCtD
Darifenacin—Syncope—Docetaxel—melanoma	0.000872	0.00254	CcSEcCtD
Darifenacin—Palpitations—Docetaxel—melanoma	0.000859	0.0025	CcSEcCtD
Darifenacin—Asthenia—Temozolomide—melanoma	0.000856	0.00249	CcSEcCtD
Darifenacin—Loss of consciousness—Docetaxel—melanoma	0.000854	0.00249	CcSEcCtD
Darifenacin—Cough—Docetaxel—melanoma	0.000848	0.00247	CcSEcCtD
Darifenacin—Diarrhoea—Carmustine—melanoma	0.000844	0.00246	CcSEcCtD
Darifenacin—Pruritus—Temozolomide—melanoma	0.000844	0.00246	CcSEcCtD
Darifenacin—Nausea—Bleomycin—melanoma	0.00084	0.00245	CcSEcCtD
Darifenacin—Hypertension—Docetaxel—melanoma	0.000839	0.00244	CcSEcCtD
Darifenacin—Vomiting—Dactinomycin—melanoma	0.000838	0.00244	CcSEcCtD
Darifenacin—Rash—Dactinomycin—melanoma	0.000831	0.00242	CcSEcCtD
Darifenacin—Arthralgia—Docetaxel—melanoma	0.000827	0.00241	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000822	0.00239	CcSEcCtD
Darifenacin—Dizziness—Carmustine—melanoma	0.000816	0.00238	CcSEcCtD
Darifenacin—Diarrhoea—Temozolomide—melanoma	0.000816	0.00238	CcSEcCtD
Darifenacin—Dry mouth—Docetaxel—melanoma	0.000809	0.00236	CcSEcCtD
Darifenacin—Confusional state—Docetaxel—melanoma	0.0008	0.00233	CcSEcCtD
Darifenacin—Oedema—Docetaxel—melanoma	0.000793	0.00231	CcSEcCtD
Darifenacin—Anaphylactic shock—Docetaxel—melanoma	0.000793	0.00231	CcSEcCtD
Darifenacin—Dizziness—Temozolomide—melanoma	0.000789	0.0023	CcSEcCtD
Darifenacin—Infection—Docetaxel—melanoma	0.000788	0.00229	CcSEcCtD
Darifenacin—Vomiting—Carmustine—melanoma	0.000785	0.00229	CcSEcCtD
Darifenacin—Nausea—Dactinomycin—melanoma	0.000783	0.00228	CcSEcCtD
Darifenacin—Shock—Docetaxel—melanoma	0.00078	0.00227	CcSEcCtD
Darifenacin—Rash—Carmustine—melanoma	0.000778	0.00227	CcSEcCtD
Darifenacin—Nervous system disorder—Docetaxel—melanoma	0.000778	0.00227	CcSEcCtD
Darifenacin—Dermatitis—Carmustine—melanoma	0.000777	0.00226	CcSEcCtD
Darifenacin—Tachycardia—Docetaxel—melanoma	0.000774	0.00225	CcSEcCtD
Darifenacin—Headache—Carmustine—melanoma	0.000773	0.00225	CcSEcCtD
Darifenacin—Skin disorder—Docetaxel—melanoma	0.00077	0.00224	CcSEcCtD
Darifenacin—Vomiting—Temozolomide—melanoma	0.000758	0.00221	CcSEcCtD
Darifenacin—Rash—Temozolomide—melanoma	0.000752	0.00219	CcSEcCtD
Darifenacin—Dermatitis—Temozolomide—melanoma	0.000751	0.00219	CcSEcCtD
Darifenacin—Headache—Temozolomide—melanoma	0.000747	0.00218	CcSEcCtD
Darifenacin—Nausea—Carmustine—melanoma	0.000733	0.00213	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Docetaxel—melanoma	0.000723	0.0021	CcSEcCtD
Darifenacin—Insomnia—Docetaxel—melanoma	0.000717	0.00209	CcSEcCtD
Darifenacin—Nausea—Temozolomide—melanoma	0.000708	0.00206	CcSEcCtD
Darifenacin—Dyspnoea—Docetaxel—melanoma	0.000707	0.00206	CcSEcCtD
Darifenacin—Somnolence—Docetaxel—melanoma	0.000705	0.00205	CcSEcCtD
Darifenacin—Dyspepsia—Docetaxel—melanoma	0.000698	0.00203	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Docetaxel—melanoma	0.000685	0.00199	CcSEcCtD
Darifenacin—Constipation—Docetaxel—melanoma	0.000678	0.00198	CcSEcCtD
Darifenacin—Pain—Docetaxel—melanoma	0.000678	0.00198	CcSEcCtD
Darifenacin—Feeling abnormal—Docetaxel—melanoma	0.000654	0.0019	CcSEcCtD
Darifenacin—Gastrointestinal pain—Docetaxel—melanoma	0.000649	0.00189	CcSEcCtD
Darifenacin—Abdominal pain—Docetaxel—melanoma	0.000627	0.00183	CcSEcCtD
Darifenacin—Hypersensitivity—Docetaxel—melanoma	0.000584	0.0017	CcSEcCtD
Darifenacin—Asthenia—Docetaxel—melanoma	0.000569	0.00166	CcSEcCtD
Darifenacin—Pruritus—Docetaxel—melanoma	0.000561	0.00163	CcSEcCtD
Darifenacin—Diarrhoea—Docetaxel—melanoma	0.000543	0.00158	CcSEcCtD
Darifenacin—Dizziness—Docetaxel—melanoma	0.000524	0.00153	CcSEcCtD
Darifenacin—Vomiting—Docetaxel—melanoma	0.000504	0.00147	CcSEcCtD
Darifenacin—Rash—Docetaxel—melanoma	0.0005	0.00146	CcSEcCtD
Darifenacin—Dermatitis—Docetaxel—melanoma	0.0005	0.00145	CcSEcCtD
Darifenacin—Headache—Docetaxel—melanoma	0.000497	0.00145	CcSEcCtD
Darifenacin—Fexofenadine—ABCB1—melanoma	0.000486	0.135	CrCbGaD
Darifenacin—Nausea—Docetaxel—melanoma	0.000471	0.00137	CcSEcCtD
Darifenacin—Clotrimazole—ABCB1—melanoma	0.000376	0.104	CrCbGaD
Darifenacin—Fentanyl—ABCB1—melanoma	0.000321	0.0892	CrCbGaD
Darifenacin—Loperamide—ABCB1—melanoma	0.00031	0.0859	CrCbGaD
Darifenacin—Methadone—ABCB1—melanoma	0.00022	0.0612	CrCbGaD
Darifenacin—CHRM1—Signaling Pathways—HIF1A—melanoma	2.61e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HIF1A—melanoma	2.61e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—PIK3CA—melanoma	2.59e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HIF1A—melanoma	2.58e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MDM2—melanoma	2.58e-05	0.000116	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—VCAN—melanoma	2.55e-05	0.000114	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ERBB2—melanoma	2.54e-05	0.000114	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCL8—melanoma	2.51e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CB—melanoma	2.51e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KDR—melanoma	2.5e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—HRAS—melanoma	2.5e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KDR—melanoma	2.49e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KDR—melanoma	2.47e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1B—melanoma	2.46e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AKT1—melanoma	2.43e-05	0.000109	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CD—melanoma	2.41e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL8—melanoma	2.41e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CASP3—melanoma	2.41e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—FN1—melanoma	2.41e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL2—melanoma	2.4e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—FN1—melanoma	2.4e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—HRAS—melanoma	2.39e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—melanoma	2.39e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—melanoma	2.38e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—FN1—melanoma	2.38e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOTCH1—melanoma	2.35e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1B—melanoma	2.35e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOTCH1—melanoma	2.35e-05	0.000105	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCND1—melanoma	2.34e-05	0.000105	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AKT1—melanoma	2.33e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOTCH1—melanoma	2.32e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CTNNB1—melanoma	2.32e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CD80—melanoma	2.31e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CASP3—melanoma	2.3e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CG—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KIT—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APC—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—NRAS—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL2—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CD80—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APC—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KIT—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CG—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—NRAS—melanoma	2.3e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—melanoma	2.29e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CD80—melanoma	2.28e-05	0.000102	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ABCB1—melanoma	2.28e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGF—melanoma	2.28e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CG—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KIT—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APC—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—NRAS—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGF—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1A—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PTEN—melanoma	2.26e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NFKB1—melanoma	2.25e-05	0.000101	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGF—melanoma	2.25e-05	0.000101	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCND1—melanoma	2.24e-05	0.000101	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CTNNB1—melanoma	2.22e-05	9.98e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—melanoma	2.21e-05	9.91e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—MAPK3—melanoma	2.21e-05	9.9e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—MAPK3—melanoma	2.2e-05	9.87e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—melanoma	2.18e-05	9.78e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—MAPK3—melanoma	2.18e-05	9.78e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1A—melanoma	2.17e-05	9.75e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PTEN—melanoma	2.17e-05	9.72e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—BRAF—melanoma	2.16e-05	9.72e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—BRAF—melanoma	2.16e-05	9.69e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NFKB1—melanoma	2.16e-05	9.68e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP17A1—melanoma	2.15e-05	9.65e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—BRAF—melanoma	2.14e-05	9.6e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—melanoma	2.11e-05	9.49e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IGF1—melanoma	2.11e-05	9.47e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CB—melanoma	2.1e-05	9.45e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IGF1—melanoma	2.1e-05	9.44e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—MAPK1—melanoma	2.1e-05	9.42e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—melanoma	2.1e-05	9.42e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PRKCA—melanoma	2.1e-05	9.41e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—MAPK1—melanoma	2.09e-05	9.39e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—melanoma	2.09e-05	9.39e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—melanoma	2.08e-05	9.36e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IGF1—melanoma	2.08e-05	9.35e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ERCC2—melanoma	2.08e-05	9.33e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—MAPK1—melanoma	2.07e-05	9.3e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—melanoma	2.07e-05	9.3e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—melanoma	2.04e-05	9.17e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAP2K1—melanoma	2.04e-05	9.15e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAP2K1—melanoma	2.03e-05	9.12e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GNA11—melanoma	2.03e-05	9.11e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CD—melanoma	2.02e-05	9.09e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—STAT3—melanoma	2.02e-05	9.08e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CD—melanoma	2.02e-05	9.06e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NRAS—melanoma	2.02e-05	9.06e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAP2K1—melanoma	2.01e-05	9.03e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	2.01e-05	9e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CA—melanoma	2e-05	8.98e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CD—melanoma	2e-05	8.97e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—FASN—melanoma	1.98e-05	8.91e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—KRAS—melanoma	1.98e-05	8.9e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CA—melanoma	1.98e-05	8.89e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—KRAS—melanoma	1.98e-05	8.87e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—KRAS—melanoma	1.96e-05	8.79e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—melanoma	1.96e-05	8.78e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC5A5—melanoma	1.95e-05	8.77e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—FGF2—melanoma	1.94e-05	8.7e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—STAT3—melanoma	1.94e-05	8.7e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK3—melanoma	1.93e-05	8.68e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—FGF2—melanoma	1.93e-05	8.68e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NRAS—melanoma	1.93e-05	8.68e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—FGF2—melanoma	1.91e-05	8.59e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GNAQ—melanoma	1.89e-05	8.47e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CD44—melanoma	1.89e-05	8.47e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MYC—melanoma	1.88e-05	8.44e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK3—melanoma	1.85e-05	8.31e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK1—melanoma	1.84e-05	8.26e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—melanoma	1.84e-05	8.25e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CA—melanoma	1.82e-05	8.18e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTEN—melanoma	1.82e-05	8.16e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CA—melanoma	1.82e-05	8.15e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MDM2—melanoma	1.81e-05	8.14e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1B1—melanoma	1.81e-05	8.12e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MDM2—melanoma	1.81e-05	8.12e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MYC—melanoma	1.8e-05	8.08e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CA—melanoma	1.8e-05	8.07e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MDM2—melanoma	1.79e-05	8.04e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ERBB2—melanoma	1.79e-05	8.03e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ERBB2—melanoma	1.78e-05	8e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ERBB2—melanoma	1.76e-05	7.93e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CB—melanoma	1.76e-05	7.92e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK1—melanoma	1.76e-05	7.91e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—melanoma	1.76e-05	7.9e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CB—melanoma	1.76e-05	7.9e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CB—melanoma	1.74e-05	7.82e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KRAS—melanoma	1.74e-05	7.8e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL8—melanoma	1.7e-05	7.61e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL8—melanoma	1.69e-05	7.59e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—HRAS—melanoma	1.68e-05	7.57e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—HRAS—melanoma	1.68e-05	7.54e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL8—melanoma	1.67e-05	7.52e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—HRAS—melanoma	1.66e-05	7.47e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KRAS—melanoma	1.66e-05	7.47e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1B—melanoma	1.66e-05	7.44e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1B—melanoma	1.65e-05	7.41e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CG—melanoma	1.64e-05	7.37e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—melanoma	1.64e-05	7.36e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1B—melanoma	1.63e-05	7.34e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—melanoma	1.63e-05	7.33e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CASP3—melanoma	1.62e-05	7.29e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL2—melanoma	1.62e-05	7.28e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CASP3—melanoma	1.62e-05	7.26e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—melanoma	1.62e-05	7.26e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL2—melanoma	1.62e-05	7.25e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—melanoma	1.61e-05	7.24e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—melanoma	1.61e-05	7.22e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CASP3—melanoma	1.6e-05	7.19e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL2—melanoma	1.6e-05	7.18e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CA—melanoma	1.6e-05	7.16e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—melanoma	1.59e-05	7.15e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARG—melanoma	1.58e-05	7.11e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCND1—melanoma	1.58e-05	7.09e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCND1—melanoma	1.57e-05	7.07e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CTNNB1—melanoma	1.56e-05	7.03e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CTNNB1—melanoma	1.56e-05	7e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCND1—melanoma	1.56e-05	7e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CTNNB1—melanoma	1.54e-05	6.93e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—melanoma	1.54e-05	6.93e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—melanoma	1.53e-05	6.89e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—melanoma	1.53e-05	6.87e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1A—melanoma	1.53e-05	6.86e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CA—melanoma	1.53e-05	6.86e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PTEN—melanoma	1.52e-05	6.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1A—melanoma	1.52e-05	6.84e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PTEN—melanoma	1.52e-05	6.83e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NFKB1—melanoma	1.52e-05	6.81e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—melanoma	1.51e-05	6.8e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NFKB1—melanoma	1.51e-05	6.79e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1A—melanoma	1.51e-05	6.77e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PTEN—melanoma	1.51e-05	6.76e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NFKB1—melanoma	1.5e-05	6.73e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCB1—melanoma	1.49e-05	6.69e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—melanoma	1.49e-05	6.68e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—melanoma	1.48e-05	6.66e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—melanoma	1.48e-05	6.64e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HRAS—melanoma	1.48e-05	6.63e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—melanoma	1.47e-05	6.59e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CD—melanoma	1.44e-05	6.48e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—melanoma	1.42e-05	6.4e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HRAS—melanoma	1.41e-05	6.35e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—melanoma	1.41e-05	6.34e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—melanoma	1.38e-05	6.18e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—melanoma	1.37e-05	6.16e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PRKCA—melanoma	1.37e-05	6.15e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STAT3—melanoma	1.36e-05	6.12e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NRAS—melanoma	1.36e-05	6.11e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—melanoma	1.36e-05	6.1e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STAT3—melanoma	1.36e-05	6.1e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ERCC2—melanoma	1.36e-05	6.1e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NRAS—melanoma	1.36e-05	6.09e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—melanoma	1.35e-05	6.07e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STAT3—melanoma	1.35e-05	6.04e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NRAS—melanoma	1.34e-05	6.03e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—melanoma	1.3e-05	5.85e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK3—melanoma	1.3e-05	5.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK3—melanoma	1.3e-05	5.83e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK3—melanoma	1.29e-05	5.78e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CA—melanoma	1.28e-05	5.76e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MYC—melanoma	1.27e-05	5.69e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MYC—melanoma	1.26e-05	5.67e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CB—melanoma	1.26e-05	5.65e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MYC—melanoma	1.25e-05	5.62e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—melanoma	1.25e-05	5.6e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—melanoma	1.25e-05	5.6e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK1—melanoma	1.24e-05	5.57e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—melanoma	1.24e-05	5.57e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK1—melanoma	1.24e-05	5.55e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—melanoma	1.24e-05	5.55e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK1—melanoma	1.22e-05	5.5e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—melanoma	1.22e-05	5.49e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KRAS—melanoma	1.17e-05	5.26e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KRAS—melanoma	1.17e-05	5.24e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KRAS—melanoma	1.16e-05	5.19e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTEN—melanoma	1.09e-05	4.88e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CA—melanoma	1.08e-05	4.83e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CG—melanoma	1.07e-05	4.82e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CA—melanoma	1.07e-05	4.82e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CA—melanoma	1.06e-05	4.77e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—melanoma	1.05e-05	4.7e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—melanoma	1.04e-05	4.67e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—melanoma	1.04e-05	4.66e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARG—melanoma	1.04e-05	4.65e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—melanoma	1.03e-05	4.61e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HRAS—melanoma	9.95e-06	4.47e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HRAS—melanoma	9.92e-06	4.45e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HRAS—melanoma	9.82e-06	4.41e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—melanoma	9.52e-06	4.28e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—melanoma	9.49e-06	4.26e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CD—melanoma	9.43e-06	4.24e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—melanoma	9.4e-06	4.22e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—melanoma	9.31e-06	4.18e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—melanoma	8.79e-06	3.95e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—melanoma	8.76e-06	3.93e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—melanoma	8.67e-06	3.9e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CB—melanoma	8.22e-06	3.69e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—melanoma	8.15e-06	3.66e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CA—melanoma	7.67e-06	3.44e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTEN—melanoma	7.11e-06	3.19e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—melanoma	6.26e-06	2.81e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CA—melanoma	5.01e-06	2.25e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—melanoma	4.09e-06	1.84e-05	CbGpPWpGaD
